Clinical trials: open to volunteers, in Uzbekistan
Symptomatic Tricuspid Regurgitation (TR) Graded as Severe or Greater
First-in-man Trial to Assess the Safety, Performance and Clinical Benefit of the TRICENTO G2 Transcatheter Valve System for Tricuspid Regurgitation
The goal of this clinical trial is to assess if the TRICENTO G2 Transcatheter Valve System for Tricuspid Regurgitation (TRICENTO G2 TVSTR) is safe and efficient in treating severe tricuspid regurgitation in adult patients.
- Trial name
- FIM-TRICSTER (NCT07536724)
- Testing
- TRICENTOG2 Transcatheter Valve System for Tricuspid Regurgitation (TRICENTOG2 TVSTR)
- Where
- 2 sites in Uzbekistan
- Volunteers
- 10 people
- Sponsor
- Medira GmbH
Colorectal Cancer
ColoSeal™ ICD System Safety and Feasibility Studies
The studies aim to evaluate the safety and feasibility of the ColoSeal Intraluminal Colonic Diversion (ICD) System in two prospective, multicenter, single-arm studies.
- Trial name
- PROTECT I (NCT06402188)
- Testing
- ColoSeal ICD Device
- Where
- 3 sites in Armenia, Georgia and 1 more
- Volunteers
- 90 people
- Sponsor
- Averto Medical, Inc.
Chronic Hepatitis D Infection
A Trial Evaluating Brelovitug (BJT-778) vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE-2)
This is a Phase 3, global, randomized, open-label, multicenter, trial evaluating brelovitug (BJT-778) vs bulevirtide for the treatment of chronic hepatitis delta infection (CHD).
- Trial name
- NCT07200908
- Testing
- Brelovitug 300 mg, Bulevirtide 2 mg and Brelovitug - 300 mg
- Where
- 57 sites in Austria, Czechia and 10 more
- Volunteers
- 172 people
- Sponsor
- Mirum Pharmaceuticals, Inc.
Type B Aortic Dissection
EXtensive mulTilayer stEnt treatmeNt in Aortic disSectiOn
This clinical trial is a prospective, multicenter, open label study designed to evaluate the effectiveness and the safety of the Allay® Aortic Stent as adjunctive endovascular treatment of Type B aortic dissection in patients…
- Trial name
- EXTENSO (NCT06675617)
- Testing
- Allay Aortic Stent
- Where
- 21 sites in Austria, Belgium and 6 more
- Volunteers
- 72 people
- Sponsor
- Intressa Vascular SA
Coronary Artery Disease, Coronary Artery Disease (CAD) (E.G., Angina, Myocardial Infarction, and Atherosclerotic Heart Disease (ASHD))
First-in-Human Study Using the SiroMax™ Sirolimus-Coated Balloon Catheter as a Percutaneous Transluminal Coronary Angioplasty (PTCA) Balloon Catheter to Treat Subjects Who Have Coronary Artery Disease (CAD) Involving In-Stent Restenosis (ISR) or an Unstented Lesion in a Small Coronary Vessel (DNSV).
The goal of this clinical trial is to learn if the SiroMax™ drug-coated balloon catheter is safe and works to treat stenotic coronary lesions in adults.
- Conditions
- Coronary Artery Disease, Coronary Artery Disease (CAD) (E.G., Angina, Myocardial Infarction, and Atherosclerotic Heart Disease (ASHD)), In-Stent Restenosis or De Novo Coronary Artery Lesions, In-Stent Stenosis (Restenosis) of Coronary Artery Stent
- Trial name
- SMART-I (NCT07811024)
- Testing
- Sirolimus-coated balloon catheter
- Where
- 2 sites in Uzbekistan
- Volunteers
- 60 people
- Sponsor
- Tonic Medical, Inc.
Acute Decompensated Heart Failure (ADHF)
Evaluation of FlowMod System While Intermittently Partially Occluding Vena Cava Blood Flow in Subjects With ADHF
FLOW-HF will assess the impact of intermittent partial occlusion of the SVC and/or IVC, the cardiac filling pressure and the difference of effects between the two occlusion locations (SVC and IVC) using the FlowMod flow…
- Trial name
- FLOW-HF (NCT07810335)
- Testing
- FlowMod System in subjects with acute decompensated heart failure (ADHF)
- Where
- 4 sites in Georgia, Uzbekistan
- Volunteers
- 30 people
- Sponsor
- FlowMod, Inc.
Acute Myeloid Leukemia
A Phase 1b Study of Lonitoclax + Azacitidine in Acute Myeloid Leukemia Patients
This is a clinical study aiming to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of ZE50-0134 in relapsed and refractory Acute Myeloid Leukemia patients.
- Trial name
- NCT07303660
- Testing
- ZE50-0134, Azacitidine Days 1-7, ZE 50-0134
- Where
- 6 sites in Russia, Uzbekistan
- Volunteers
- 66 people
- Sponsor
- Lomond Therapeutics Holdings, Inc.
Advanced Solid Tumor Cancer, Metastatic Solid Tumor
A First-in-Human Study of ZE94-0605 in Patients With Advanced Solid Tumors
ZE94-0605 is an oral, selective cyclin-dependent kinase 2 (CDK2) inhibitor. This multicenter, open-label, first-in-human Phase 1 study will evaluate ZE94-0605 in adults with advanced, unresectable or metastatic solid tumors.
- Trial name
- NCT07524140
- Testing
- ZE94-0605
- Where
- 3 sites in Australia, Uzbekistan
- Volunteers
- 60 people
- Sponsor
- Eilean Therapeutics
Degenerative Disc Disease, Chronic Low-back Pain
"Lumbar Operatively Inserted PerQdisc Artificial Implant Following Nulcectomy" (LOPAIN2)
This study will be a prospective, open-label, multi-center study including 72 patients that will collect additional safety and efficacy data for the Spinal Stabilization Technologies PerQdisc Nucleus Replacement System.
- Trial name
- LOPAIN2 (NCT05508360)
- Testing
- PerQdisc Nucleus Replacement System
- Where
- 11 sites in Colombia, Costa Rica and 3 more
- Volunteers
- 72 people
- Sponsor
- Spinal Stabilization Technologies
COVID - 19
Early-stage Trial to Determine a Safe and Effective Dose for Ratutrelvir in Patients With Mild to Moderate COVID-19
This is an Early-stage Clinical Trial to Determine a Safe and Effective Dose for Ratutrelvir in Patients With Mild to Moderate COVID-19. It will also learn about the safety of drug Ratutrelvir.
- Trial name
- NCT07157007
- Testing
- Ratutrelvir (83-0060) non-randomised, Paxlovid, Ratutrelvir (83-0060)
- Where
- 15 sites in Australia, South Korea and 2 more
- Volunteers
- 90 people
- Sponsor
- Traws Pharma, Inc.
Aneurysm, Abdominal Aortic
First-in-Human Trial of the A3-Shield System for Stabilizing Abdominal Aortic Aneurysms
This clinical trial evaluates the safety and feasibility of the A3-Shield implant for stabilising small abdominal aortic aneurysms in adult patients.
- Trial name
- PRINCIPIIS-FIH (NCT07330752)
- Testing
- A3-Shield Implantation
- Where
- Uzbekistan
- Volunteers
- 12 people
- Sponsor
- Angiolutions GmbH
Plantar Fascitis, Heel Pain
SakuraBead Used as Resorbable Embolic for Plantar Fascia Embolization
This is a prospective, single center, double arm, randomized, unmasked, First in Human study that aims to evaluate the safety and effectiveness of SakuraBead™ resorbable embolization microspheres in adult patients suffering from…
- Conditions
- Plantar Fascitis, Heel Pain, Musculoskeletal Diseases
- Trial name
- SURE-PF (NCT07241884)
- Testing
- Arterial Embolization, Extracorporeal shockwave therapy
- Where
- Uzbekistan
- Volunteers
- 45 people
- Sponsor
- CrannMed
Atrial Fibrillation
Safety and Performance of ENDOMATIC SEPIOLA Left Atrial Appendage (LAA) Closure Device
The study is designed to evaluate the safety and performance of the ENDOMATIC SEPIOLA Left Atrial Appendage (LAA) Closure Device in Patients with non-valvular Atrial Fibrillation, who are at increased risk for stroke, and that…
- Trial name
- NCT06099106
- Testing
- SEPIOLA System
- Where
- 5 sites in Georgia, Lithuania and 2 more
- Volunteers
- 15 people
- Sponsor
- Endomatic Ltd.
Viral Enteric Infection
Trial of the Efficacy and Safety of Use of Drug Product Reamberin® for Pathogenetic Therapy of Viral Enteric Infection in Children Aged 1-6 Years Old
To assess the efficacy and safety of use of drug product Reamberin® solution for infusion, 1.5 % (Scientific Technological Pharmaceutical Firm "POLYSAN") for pathogenetic therapy of viral enteric infection in children aged 1-6…
- Trial name
- NCT07066540
- Testing
- Reamberin® solution for infusion, 1.5 %
- Where
- 8 sites in Russia, Uzbekistan
- Volunteers
- 300 people
- Sponsor
- POLYSAN Scientific & Technological Pharmaceutical Company